ClinicalTrials.gg
RecruitingNCT07416552Updated Nov 3, 2026

A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)

A Phase 1 interventional study of SPLIT Abs and 203Pb-DOTAM in Metastatic Colorectal Cancer, sponsored by Hoffmann-La Roche. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 3, 2026Start date moved2 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
180
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 111 studies in Colorectal Neoplasms by Hoffmann-La Roche — 3 open to participants now, 6 under way, none of them phase 3. Colorectal Neoplasms · Hoffmann-La Roche.

Planned enrollment
27th of 77
180 · median 96
Started
2026
with 2 others
Phase 1
22 of 111
3 open now
Registered
110th of 111
by date

Among the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, this one is the 27th largest by planned enrollment of the 77 interventional ones that give a count, is one of 3 that started in 2026, is one of 22 in phase 1, and was the 110th registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

3 of the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study will evaluate the dosimetry, safety, efficacy, pharmacokinetics (PK), pharmacodynamics and immunogenicity of CEA-PRIT 2.0 in participants with metastatic microsatellite-stable (MSS) mCRC who are intolerant to or have progressed after having received available standard-of-care (SOC) therapies.

03

Conditions studied

  • Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed adenocarcinoma originating from the colon or rectum
  • disease (Stage IV American Joint Committee on Cancer, Version 7)
  • Confirmed MSS and/or proficient mismatch repair (MMR) status
  • Experienced disease progression during or within 3 months following the last administration of systemic anti-cancer therapies for metastatic disease
  • Presence of according to (RECIST) v1.1.
  • estimated by the Investigator to be >=12 weeks
  • (ECOG) Performance Status (PS) 0-1
  • Adequate cardiovascular, hematological and renal function and laboratory parameters

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding or intending to become pregnant
  • Participants with active central nervous system (CNS)
  • History of other than the one under investigation
  • Any unresolved toxicities from prior therapy, i.e., radiotherapy, chemotherapy, targeted therapy or surgical procedure
  • Major surgery or significant traumatic injury \<4 weeks prior to the first CEA-PRIT 2.0 administration (excluding ) or anticipation of the need for major surgery during study treatment
  • Participants have a known confirmed positive test for
  • Positive surface antigen (HBsAg) test, and/or positive total hepatitis B core Ab (HBcAb) test at screening.
  • Positive (HCV) Ab test result at screening
  • Any anticancer treatment or any agent within 4 weeks (or 5 times the half-life, whichever is shorter) prior to C1D1
  • Prior treatment with a CEA-targeted agent or systemic radio therapy
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Part 1 (Dosimetry)

    Participants will receive SeParated v-domains LInkage Technology Antibodies (SPLIT Abs) administered intravenously (IV). During Cycle 1, following an initial dosing interval, participants will receive 203Pb-DOTAM for imaging-based dosimetry assessment, followed by administration of 212Pb-DOTAM. In other cycles, participants will receive SPLIT Abs in combination with 212Pb-DOTAM only. Treatment will be administered every 4 weeks (Q4W) for up to 6 cycles. Each cycle is 28 days.

    Drug: SPLIT Abs · Drug: 203Pb-DOTAM · Drug: 212Pb-DOTAM

  • Experimental
    Part 2 (212Pb-DOTAM Administered Activity Escalation)

    Participants will receive SPLIT Abs at the dose and dosing interval selected in Part 1 in combination with 212Pb-DOTAM. The administered activity of 212Pb-DOTAM will be increased stepwise in each cohort to identify the maximum tolerated administered 212 activity (MTA) or a recommended Phase 2 administered activity (RP2A).

    Drug: SPLIT Abs · Drug: 203Pb-DOTAM · Drug: 212Pb-DOTAM

  • Experimental
    Part 3 (Expansion)

    Participants will receive SPLIT Abs in combination with 212Pb-DOTAM at the RP2A identified based on results from Parts 1 and 2.

    Drug: SPLIT Abs · Drug: 212Pb-DOTAM

Interventions

  • DrugSPLIT Abs

    Participants will receive SPLIT Abs as part of the pretargeting regimen per the schedule described in the protocol.

    Also known as: RO7782304, RO7782306

  • Drug203Pb-DOTAM

    Participants will receive 203Pb-DOTAM as an imaging surrogate per the schedule described in the protocol.

    Also known as: RO7205834-009

  • Drug212Pb-DOTAM

    Participants will receive 212Pb-DOTAM as a therapeutic radioligand per the schedule described in the protocol.

    Also known as: RO7205834-010

06

What researchers measure

Primary outcomes

  1. Part 1: Serum Concentration of SPLIT Abs

    Time frame: Up to approximately 48 weeks

  2. Part 1: Time Course of Blood, Plasma, and Urine Radioactivity for 203Pb-DOTAM

    Time frame: Up to approximately 48 weeks

  3. Part 1 to 2: Absorbed Radiation Dose of 212Pb-DOTAM extrapolated from 203Pb-DOTAM

    Time frame: Up to approximately 48 weeks

  4. Part 1 to 3: Percentage of Participants With Adverse Events (AE)

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. Part 1 to 2: Uptake of 203Pb-DOTAM in Tumor and Normal Tissue

    Time frame: Up to approximately 48 weeks

  2. Part 1 to 2: Time Course of Blood, Plasma, and Urine Radioactivity for 203Pb-DOTAM

    Time frame: Up to approximately 48 weeks

  3. Part 1 to 3: Serum Concentration of CEA-PRIT 2.0

    Time frame: Up to approximately 48 weeks

  4. Part 1 to 3: Time Course of Blood and Plasma Radioactivity for 212Pb-DOTAM

    Time frame: Up to approximately 48 weeks

  5. Part 1 to 3: Percentage of Participants With Anti-Drug Antibodies (ADAs) Against SPLIT Abs

    Time frame: Baseline, Up to approximately 48 weeks

  6. Part 1 to 3: Objective Response Rate (ORR)

    Time frame: Up to approximately 48 weeks

  7. Part 1 to 3: Disease Control Rate (DCR)

    Time frame: Up to approximately 48 weeks

  8. Part 1 to 3: Duration of Response (DOR)

    Time frame: Up to approximately 48 weeks

  9. Part 1 to 3: Progression-Free Survival (PFS)

    Time frame: Up to approximately 48 weeks

  10. Part 1 to 3: Overall Survival (OS)

    Time frame: Up to approximately 48 weeks

  11. Part 1 to 3: Correlation Between Carcinoembryogenic Antigen (CEA) Tumor Expression and Clinical Activity

    Time frame: Up to approximately 48 weeks

07

Study locations

5 of 5 sites recruiting
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Feb 2034, 87 months after the start.

Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's planned 87 months is above that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

Start moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, last on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 18, 2026
StartActual
Oct 13, 2026was Sep 2026
Primary completionEst.
Feb 12, 2034
CompletionEst.
Feb 12, 2034
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • The University of Chicago Medical Center · Chicago, United States
  • Washington University School of Medicine in St. Louis · St Louis, United States
Oct 6, 2026
Start date
Sep 8, 2026→Oct 13, 2026 (actual)
moved 2 times, Oct 6, 2026 – Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Start date Oct 6, 2026→Oct 13, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 6, 2026
    2 sites added
    Show 2 added (2 United States)
    • The University of Chicago Medical Center · Chicago, United States
    • Washington University School of Medicine in St. Louis · St Louis, United States
    Start date Sep 8, 2026→Oct 6, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07416552
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 18, 2026
Start date
Oct 13, 2026
Primary completion
Feb 12, 2034 (estimated)
Completion
Feb 12, 2034 (estimated)
Last update
Nov 3, 2026

Study contacts

Reference Study ID Number: BP45930 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. and Canada)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion